Torthaí cuardaigh - David Tougeron

Beachtaigh na torthaí
  1. 1
    Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies

    Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies de réir Violaine Randrian, Camille Evrard, David Tougeron

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    ABCB4/MDR3 gene mutations and cholangiocarcinomas

    ABCB4/MDR3 gene mutations and cholangiocarcinomas de réir David Tougeron, Ginette Fotsing, Véronique Barbu, Michel Beauchant

    Foilsithe / Cruthaithe 2012
    Faigh an téacs iomlán
    Carta
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Irreversible electroporation and electrochemotherapy in oncology: State of the art

    Irreversible electroporation and electrochemotherapy in oncology: State of the art de réir Jean‐Pierre Tasu, David Tougeron, Marie‐Pierre Rols

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Aspirin and Colorectal Cancer: Back to the Future

    Aspirin and Colorectal Cancer: Back to the Future de réir David Tougeron, Dan Sha, Sashidhar Manthravadi, Frank A. Sinicrope

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer

    Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer de réir Camille Evrard, Gaëlle Tachon, Violaine Randrian, Lucie Karayan‐Tapon, David Tougeron

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Beclin 1 and UVRAG Confer Protection from Radiation-Induced DNA Damage and Maintain Centrosome Stability in Colorectal Cancer Cells

    Beclin 1 and UVRAG Confer Protection from Radiation-Induced DNA Damage and Maintain Centrosome Stability in Colorectal Cancer Cells de réir Jae Myung Park, David Tougeron, Shengbing Huang, Koichi Okamoto, Frank A. Sinicrope

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment

    Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment de réir Julien Taı̈eb, Magali Svrcek, Romain Cohen, Debora Basile, David Tougeron, Jean-Marc Phélip

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer

    High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer de réir Marion Jeantet, David Tougeron, Gaëlle Tachon, Ulrich Cortes, Céline Archambaut, Gaëlle Fromont, Lucie Karayan‐Tapon

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer

    Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer de réir David Tougeron, F. Di Fiore, S. Thureau, N. Berbera, Isabelle Iwanicki–Caron, H. Hamidou, B Paillot, Pierre Michel

    Foilsithe / Cruthaithe 2008
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    Proof of concept and design of an externally controlled trial for patients with gastro-enteropancreatic neuroendocrine carcinomas based on the randomized phase II BEVANEC trial

    Proof of concept and design of an externally controlled trial for patients with gastro-enteropancreatic neuroendocrine carcinomas based on the randomized phase II BEVANEC trial de réir S. Ganame, T. Walter, A. Durand, Astrid Lièvre, David Tougeron, Jean–Yves Scoazec, E. Baudin, C. Lepage, Olayidé Boussari, Julien Hadoux

    Foilsithe / Cruthaithe 2025
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    Second‐line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first‐line platinum‐based chemotherapy

    Second‐line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first‐line platinum‐b... de réir Aziz Zaanan, Mélanie Gauthier, David Malka, Christophe Locher, Jean‐Marc Gornet, Anne Thirot‐Bidault, David Tougeron, Julien Taı̈eb, Franck Bonnetain, Thomas Aparicio

    Foilsithe / Cruthaithe 2010
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer

    Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer de réir David Tougeron, Thierry Lecomte, Jean‐Christophe Pagès, Claire Villalva, Christine Collin, Aurélie Ferru, J.M. Tourani, Christine Silvain, P. Levillain, L. Karayan-Tapon

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 13
    Mutation‐specific antibody detects mutant BRAF<sup>V600E</sup> protein expression in human colon carcinomas

    Mutation‐specific antibody detects mutant BRAF<sup>V600E</sup> protein expression in human colon carcinomas de réir Frank A. Sinicrope, Thomas C. Smyrk, David Tougeron, Stephen N. Thibodeau, Shalini Singh, Andrea Murányi, Kandavel Shanmugam, Thomas M. Grogan, Steven R. Alberts, Qian Shi

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  14. 14
    Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor

    Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor de réir Louis de Mestier, Thomas Walter, Camille Evrard, Paul de Boissieu, Olivia Hentic, Jérôme Cros, David Tougeron, Catherine Lombard‐Bohas, Vinciane Rebours, Pascal Hammel, Philippe Ruszniewski

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  15. 15
    COVID-19 lockdown-related treatment modifications did not impact the outcome of digestive cancers: the Clin-COVIDICA prospective study

    COVID-19 lockdown-related treatment modifications did not impact the outcome of digestive cancers: the Clin-COVIDICA prospective study de réir Violaine Randrian, Amale Dhimene, Armelle Pillet, Camille Evrard, Rayan Elfadel, Claire Boyer, Astrid Guyot d’Asnières de Salins, Isabelle Ingrand, Aurélie Ferru, Laetitia Rouleau, David Tougeron

    Foilsithe / Cruthaithe 2025
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  16. 16
    Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study

    Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study de réir Maëva Salimon, Caroline Prieux‐Klotz, David Tougeron, Vincent Hautefeuille, Morgane Caulet, Jérôme Gournay, Tamara Matysiak‐Budnik, Jaafar Bennouna, Manuela Tiako Meyo, Thierry Lecomte, Aziz Zaanan, Yann Touchefeu

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  17. 17
    “Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial”

    “Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial” de réir Julien Taı̈eb, Léonor Benhaïm, Pierre Laurent–Puig, Karine Le Malicot, Jean‐François Emile, Flore Geillon, David Tougeron, Sylvain Manfrédi, Marion Chauvenet, Valérie Taly, Côme Lepage, Thierry André

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  18. 18
    Usefulness of the Serum Carcinoembryonic Antigen Kinetic for Chemotherapy Monitoring in Patients With Unresectable Metastasis of Colorectal Cancer

    Usefulness of the Serum Carcinoembryonic Antigen Kinetic for Chemotherapy Monitoring in Patients With Unresectable Metastasis of Colorectal Cancer de réir Isabelle Iwanicki–Caron, Frédéric Di Fiore, Isabelle Roque, Emilie Astruc, Monica Stetiu, A. Duclos, David Tougeron, Sandrine Saillard, S. Thureau, Jacques Bénichou, B Paillot, J P Basuyau, Pierre Michel

    Foilsithe / Cruthaithe 2008
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  19. 19
    <i>KRAS</i> Codon 12 and 13 Mutations in Relation to Disease-Free Survival in <i>BRAF</i>–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)

    <i>KRAS</i> Codon 12 and 13 Mutations in Relation to Disease-Free Survival in <i>BRAF</i>–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance) de réir Harry H. Yoon, David Tougeron, Qian Shi, Steven R. Alberts, Michelle R. Mahoney, Garth D. Nelson, Suresh Nair, Stephen N. Thibodeau, Richard M. Goldberg, Daniel J. Sargent, Frank A. Sinicrope

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  20. 20
    Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

    Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter stu... de réir Antoine Adenis, Christelle de la Fouchardière, Bernard Paule, Pascal Burtin, David Tougeron, Jennifer Wallet, Louis-Marie Dourthe, Pierre-Luc Etienne, Laurent Mineur, Stéphanie Clisant, Jean-Marc Phélip, Andrew Kramar, Thierry André

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: